Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor
Copyright 2000 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2000
In Reply: We have previously addressed the
issues raised by Drs Pèrez-Molina and Fernández.1
As we have stated, resistance testing (genotypic as well as phenotypic) should
be viewed in the context of many other factors when choosing drug therapy.
Such factors include treatment history, viral load, medication tolerance,
adherence, and concomitant medical conditions. Pèrez-Molina and Fernández
raise a theoretical concern regarding linkage of mutations that we have discussed
previously1 and that may apply to phenotyping
as well as genotyping.
Hirsch MS, Richman DD. The Role of Genotypic Resistance Testing in Selecting Therapy for HIV—Reply. JAMA. 2000;284(13):1649-1650. doi:10.1001/jama.284.13.1647